Remove 2025 Remove Clinical Supply Remove Drugs
article thumbnail

Enhancing Your Experience: What to Expect From Us in 2025

PPD

Unlocking new levels of value with expanded offerings We are launching more dynamic and integrated service offerings that leverage the very latest automation and integrations to accelerate your unique drug development journey in new and different ways. Contact your business development representative to learn more.

article thumbnail

A Biotech Midsummer’s Madness

LifeSciVC

At this point of the year, the JPMorgan conference seems like ancient history and you are looking into flights for JPM 2025. Drug development is a long process, and patients are waiting. What has the impact of summer been on recruiting efforts and the ability to manage clinical trial participants? Do you have ample drug supply?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Transform Your CDMO Experience By Choosing The Right Partner

Fierce BioTech

Transform Your CDMO Experience By Choosing The Right Partner Learn how the right CDMO partner can help biopharma companies navigate challenges and accelerate drug development. sdees Thu, 02/06/2025 - 11:32 Learn how the right CDMO partner can help biopharma companies navigate challenges and accelerate drug development.

article thumbnail

The golden era of GLP-1 drugs: How will it impact medicine and society?

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Sponsored The golden era of GLP-1 drugs: How will it impact medicine and society? The potential to reduce these risks with a single drug class is monumental.

article thumbnail

FDA’s AI tool ‘Elsa’ is here, and the industry has questions

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from FDA’s AI tool ‘Elsa’ is here, and the industry has questions The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool’s rollout.

FDA 130
article thumbnail

[Podcast] Trial Trailblazers: Behind clinical breakthroughs

BioPharma Drive: Drug Pricing

Editors picks Permission granted by Daiichi Sankyo ASCO25 Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Its new CEO has to figure out what’s next. Hiroyuki Okuzawa is working to keep it that way.

Trials 130